EpiPen Pricing Got Mylan In Hot Water; Now Sanofi Is Taking Firm To Court

Sanofi claims Mylan blocked its competing Auvi-Q product from the market by offering rebates to payers on the condition they would only reimburse for EpiPen; Sanofi seeks treble damages for lost sales.

EpiPen

Eighteen months after Sanofi discontinued marketing Auvi-Q (epinephrine auto-injector), it has filed an antitrust suit against Mylan NV claiming the EpiPen maker blocked its access to the market.

The complaint, filed April 24 in the US District Court for the District of New Jersey, alleges that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet